Oncotarget

Research Papers:

Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer

Amit Katz, Uri Barash, Ilanit Boyango, Sari Feld, Yaniv Zohar, Edward Hammond, Neta Ilan, Ran Kremer and Israel Vlodavsky _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:19294-19306. https://doi.org/10.18632/oncotarget.25022

Metrics: PDF 1387 views  |   HTML 2001 views  |   ?  


Abstract

Amit Katz1, Uri Barash2, Ilanit Boyango2, Sari Feld2, Yaniv Zohar3, Edward Hammond4, Neta Ilan2, Ran Kremer1 and Israel Vlodavsky2

1Department of General Thoracic Surgery, Rambam Health Care Campus, Haifa, Israel

2Cancer and Vascular Biology Research Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel

3Department of Pathology, Rambam Health Care Campus, Haifa, Israel

4Zucero Therapeutics, Brisbane, Queensland, Australia

Correspondence to:

Israel Vlodavsky, email: vlodavsk@mail.huji.ac.il

Keywords: heparanase; lung cancer; PDX; PG545; metastasis

Received: February 06, 2018     Accepted: March 17, 2018     Published: April 10, 2018

ABSTRACT

Heparanase, the sole heparan sulfate (HS) degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis, and inflammation. Heparanase accomplishes this by degrading HS and thereby facilitating cell invasion and regulating the bioavailability of heparin-binding proteins. HS mimicking compounds that inhibit heparanase enzymatic activity were examined in numerous preclinical cancer models. While these studies utilized established tumor cell lines, the current study utilized, for the first time, patient-derived xenografts (PDX) which better resemble the behavior and drug responsiveness of a given cancer patient. We have previously shown that heparanase levels are substantially elevated in lung cancer, correlating with reduced patients survival. Applying patient-derived lung cancer xenografts and a potent inhibitor of heparanase enzymatic activity (PG545) we investigated the significance of heparanase in the pathogenesis of lung cancer. PG545 was highly effective in lung cancer PDX, inhibiting tumor growth in >85% of the cases. Importantly, we show that PG545 was highly effective in PDX that did not respond to conventional chemotherapy (cisplatin) and vice versa. Moreover, we show that spontaneous metastasis to lymph nodes is markedly inhibited by PG545 but not by cisplatin. These results reflect the variability among patients and strongly imply that PG545 can be applied for lung cancer therapy in a personalized manner where conventional chemotherapy fails, thus highlighting the potential benefits of developing anti-heparanase treatment modalities for oncology.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25022